[Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate].
In an open randomized cross-over study 800 mg cyclandelate (Natil, CAS 456-59-7) was applicated to 24 young, male volunteers. Before and during 24 h after application of a single dose a 17-channel, quantitative topographical pharmaco-EEG was recorded. A significant increase of the spectral power density was observed in the alpha 2, beta 1 and beta 2 frequency bands starting 2 h after application until 4.5 h. The increase in beta 1 and beta 2 power was observed in the parietocentral area of the cortex. The difference between the circadian development of the EEG power and the development after medication was obvious after 3 until 4.5 h. For the beta frequencies only a weak statistical confirmation could be obtained, but for the alpha 2 frequency a significant difference between the circadian and the EEG power under cyclandelate was found using the sign test. Altogether a quantitative effect on brain activity was detected after oral application of cyclandelate, reaching its maximum before the blood concentration of the metabolites cyclandic glucuronide and mandelic acid reached their peak heights.
Dimpfel
W
W
Pro Science Private Research Institute GmbHa, Linden.
Schober
F
F
Wedekind
W
W
Kleinbloesem
C
C
Coors
C
C
D000328:Adult; D001711:Biotransformation; D002940:Circadian Rhythm / Q000502:physiology; D018592:Cross-Over Studies; D003495:Cyclandelate / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004569:Electroencephalography / Q000187:drug effects*; D006801:Humans; D008297:Male
D003495:Cyclandelate
Nachweis pharmakokinetischer-pharmakodynamischer Beziehungen mittels Pharmako-EEG bei gesunden Probanden nach Verabreichung von Cyclandelat.